Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches

The sialic acid-binding immunoglobulin-like lectin (Siglec)-sialic acid immune axis is an evolutionarily conserved immunoregulatory pathway that provides a mechanism for establishing self-recognition and combatting invasive pathogens. Perturbations in the pathway lead to many immune dysregulated dis...

Full description

Saved in:
Bibliographic Details
Published inCancer immunology research Vol. 10; no. 12; p. 1423
Main Authors Läubli, Heinz, Nalle, Sam C, Maslyar, Daniel
Format Journal Article
LanguageEnglish
Published United States 02.12.2022
Subjects
Autoimmunity
Humans
Immunity
N-Acetylneuraminic Acid - metabolism
Neoplasms
Sialic Acid Binding Immunoglobulin-like Lectins
Online AccessGet more information

Cover

More Information
Summary:The sialic acid-binding immunoglobulin-like lectin (Siglec)-sialic acid immune axis is an evolutionarily conserved immunoregulatory pathway that provides a mechanism for establishing self-recognition and combatting invasive pathogens. Perturbations in the pathway lead to many immune dysregulated diseases, including autoimmunity, neurodegeneration, allergic conditions, and cancer. The purpose of this review is to provide a brief overview of the relationship between Siglecs and sialic acid as they relate to human health and disease, to consider current Siglec-based therapeutics, and to discuss new therapeutic approaches targeting the Siglec-sialic acid immune axis, with a focus on cancer.
ISSN:2326-6074
DOI:10.1158/2326-6066.CIR-22-0366